120 related articles for article (PubMed ID: 33113046)
21. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
22. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
23. Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review.
Alshemmari SH; Rajan R; Emadi A
Med Princ Pract; 2016; 25(6):501-509. PubMed ID: 27756071
[TBL] [Abstract][Full Text] [Related]
24. Mutations and prognosis in primary myelofibrosis.
Vannucchi AM; Lasho TL; Guglielmelli P; Biamonte F; Pardanani A; Pereira A; Finke C; Score J; Gangat N; Mannarelli C; Ketterling RP; Rotunno G; Knudson RA; Susini MC; Laborde RR; Spolverini A; Pancrazzi A; Pieri L; Manfredini R; Tagliafico E; Zini R; Jones A; Zoi K; Reiter A; Duncombe A; Pietra D; Rumi E; Cervantes F; Barosi G; Cazzola M; Cross NC; Tefferi A
Leukemia; 2013 Sep; 27(9):1861-9. PubMed ID: 23619563
[TBL] [Abstract][Full Text] [Related]
25. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.
Guglielmelli P; Pacilli A; Rotunno G; Rumi E; Rosti V; Delaini F; Maffioli M; Fanelli T; Pancrazzi A; Pietra D; Salmoiraghi S; Mannarelli C; Franci A; Paoli C; Rambaldi A; Passamonti F; Barosi G; Barbui T; Cazzola M; Vannucchi AM;
Blood; 2017 Jun; 129(24):3227-3236. PubMed ID: 28351937
[TBL] [Abstract][Full Text] [Related]
26. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.
Kröger N; Panagiota V; Badbaran A; Zabelina T; Triviai I; Araujo Cruz MM; Shahswar R; Ayuk F; Gehlhaar M; Wolschke C; Bollin R; Walter C; Dugas M; Wiehlmann L; Lehmann U; Koenecke C; Chaturvedi A; Alchalby H; Stadler M; Eder M; Christopeit M; Göhring G; Koenigsmann M; Schlegelberger B; Kreipe HH; Ganser A; Stocking C; Fehse B; Thol F; Heuser M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1095-1101. PubMed ID: 28389256
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
[TBL] [Abstract][Full Text] [Related]
28. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
[TBL] [Abstract][Full Text] [Related]
29. Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S; Stengel R; Jaekel N; Wang SY; Franke GN; Roskos M; Schneider M; Niederwieser D; Al-Ali HK
Genes Chromosomes Cancer; 2019 Nov; 58(11):747-755. PubMed ID: 31135094
[TBL] [Abstract][Full Text] [Related]
30. A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients.
Wassie E; Finke C; Gangat N; Lasho TL; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Br J Haematol; 2015 Apr; 169(1):71-6. PubMed ID: 25521305
[TBL] [Abstract][Full Text] [Related]
31. Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
Hu Z; Ramos CEB; Medeiros LJ; Zhao C; Yin CC; Li S; Hu S; Wang W; Thakral B; Xu J; Verstovsek S; Lin P
Hum Pathol; 2019 Mar; 85():290-298. PubMed ID: 30447300
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the diagnosis and management of primary myelofibrosis.
Takenaka K; Shimoda K; Akashi K
Korean J Intern Med; 2018 Jul; 33(4):679-690. PubMed ID: 29665657
[TBL] [Abstract][Full Text] [Related]
33. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
34. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.
Agarwal A; Morrone K; Bartenstein M; Zhao ZJ; Verma A; Goel S
Stem Cell Investig; 2016; 3():5. PubMed ID: 27358897
[TBL] [Abstract][Full Text] [Related]
36. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
[TBL] [Abstract][Full Text] [Related]
37. The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms.
Byun JM; Song S; Koh Y; Yoon SS; Kim D
Anticancer Res; 2019 Nov; 39(11):6273-6282. PubMed ID: 31704857
[TBL] [Abstract][Full Text] [Related]
38. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
39. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
[TBL] [Abstract][Full Text] [Related]
40. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
